Susquehanna International Group
EVLO

Susquehanna International Group’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Susquehanna International Group’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,040
Closed -$7.34K – 13590
2023
Q1 		$7.34K Buy
+2,040
New +$31.5K ﹤0.01% 12253
2022
Q4 		– Sell
-630
Closed -$26K – 14227
2022
Q3 		$26K Buy
630
+5
+0.8% +$229 ﹤0.01% 12514
2022
Q2 		$26K Sell
625
-1,855
-75% -$86K ﹤0.01% 12292
2022
Q1 		$168K Buy
+2,480
New +$206K ﹤0.01% 11449
2021
Q4 		– Sell
-2,120
Closed -$298K – 14210
2021
Q3 		$298K Buy
2,120
+1,540
+266% +$305K ﹤0.01% 10617
2021
Q2 		$159K Sell
580
-190
-25% -$47.9K ﹤0.01% 11809
2021
Q1 		$165K Buy
+770
New +$213K ﹤0.01% 11576

Other funds holding EVLO

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Susquehanna International Group's EVLO Position: Q4 2023 in Review

Susquehanna International Group sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 26,679 shares — an estimated $105K sold.

Susquehanna International Group first reported a position in EVLO in Q3 2020 and held it in 7 quarters. The position peaked at $687K in Q1 2022. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.

  • Susquehanna International Group reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Susquehanna International Group sold 26,679 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $105K.
  • Susquehanna International Group first reported a position in Evelo Biosciences, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
  • Susquehanna International Group's Evelo Biosciences, Inc. Common Stock position peaked at $687K in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.

Based on Susquehanna International Group's 13F filing for Q4 2023, filed 14 Feb 2024.